Meeting
2020 ASCO Virtual Scientific Program
Combination immunotherapy with ipilimumab and nivolumab in patients with rare gynaecological malignancies.
Authors
Oliver Klein
Medical Oncology Unit, Austin Health, Heidelberg, Australia
Oliver Klein , Damien Kee , Bo Gao , Ben Markman , Linda R. Mileshkin , Clare L. Scott , Yeojeong So , Richelle Linklater , Andreas Behren , Jodie Palmer , Matteo S. Carlino , Jonathan S. Cebon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Other Gynecologic Cancer
Clinical Trial Registration Number
NCT02923934
Citation
J Clin Oncol 38: 2020 (suppl; abstr 6091)
DOI
10.1200/JCO.2020.38.15_suppl.6091
Abstract #
6091
Poster Bd #
262
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Combination immunotherapy with ipilimumab and nivolumab in patients with advanced biliary tract cancers.
First Author: Oliver Klein
Poster
2023 ASCO Annual Meeting
Nivolumab and ipilimumab in advanced non small cell lung cancer previously treated with PD1 axis inhibition.
First Author: Scott N. Gettinger
Poster
2023 ASCO Annual Meeting
ENVASARC: A pivotal trial of envafolimab and envafolimab in combination with ipilimumab in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy.
First Author: Richard F. Riedel
Poster
2022 ASCO Annual Meeting
Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma.
First Author: Ciara Conduit